Online inquiry

IVTScrip™ mRNA-Anti-ADAMTSL5&ALB, M-6495(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10744MR)

This product GTTS-WQ10744MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets ADAMTSL5&ALB gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Lama glama; Humanized
RefSeq NM_213604.3; NM_000477.7
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 339366; 213
UniProt ID Q6ZMM2; P02768
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ADAMTSL5&ALB, M-6495(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ10744MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8666MR IVTScrip™ mRNA-Anti-CD38, HuMax-CD38(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA HuMax-CD38
GTTS-WQ6156MR IVTScrip™ mRNA-Anti-IGF1R, CP-751871(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CP-751871
GTTS-WQ7662MR IVTScrip™ mRNA-Anti-TNFRSF10B, GEN-1029(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA GEN-1029
GTTS-WQ46MR IVTScrip™ mRNA-Anti-TNFRSF17, 2857916(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 2857916
GTTS-WQ6378MR IVTScrip™ mRNA-Anti-Factor IX substitute, CSL654(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CSL654
GTTS-WQ13084MR IVTScrip™ mRNA-Anti-MADCAM1, PF-00547659(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PF-00547659
GTTS-WQ12015MR IVTScrip™ mRNA-Anti-ERBB2, MM-302(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MM-302
GTTS-WQ1743MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ADCT-301
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW